Biotechnology Assets

Biotechnology Assets. Shall mean all hybridomas owned or Controlled by Coulter as of the Effective Date. Such hybridomas shall include, but not be limited to, those capable of producing the monoclonal antibodies ("MABs") listed below. The parties agree and acknowledge that: (1) the hybridomas which are capable of producing the Dana-Farber MABs listed below are Controlled by Coulter pursuant to one or more of the Dana-Farber License Agreements; and (2) the MABs marked with an asterisk (*) are subject to the terms of... the Ortho Settlement Agreement. Coulter MABs Dana-Farber MABs [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] View More